The goal of this proposal is to expand the use of a novel C. elegans tissue-model of radiation-induced reproductive cell death (""""""""Radelegans"""""""") to better define the genetic basis of the radioresponse. Reproductive cell death is the primary form of target """"""""clonogen"""""""" cell death after radiotherapy, and Radelegans is the first in vivo model of reproductive cell death in isolation of other forms of cell death, allowing the genetic dissection of the radiation response. This work is the natural expansion of Radelegans (designed by the principal investigator) in a direction that will allow the creation of interesting hypothesis as well as the potential for meaningful discoveries in the field of cancer biology.
The specific aims of this proposal are to develop Radelegans into a high-throughput screen (HTS) using RNAi (RNA interference) to allow evaluation of individual genes in the tissue and tumor-responses to radiation therapy. Concurrently, Radelegans will be used to evaluate the role of microRNA (miRNA) genes, global gene regulators, in the radiation response. Identifying the components of the complex genetic networks required for the radioresponse as well as the interaction of global gene regulators with these pathways will be a critical advance in our understanding of tissue and tumor-responses to cytotoxic therapy. This work also has the potential to identify not only new individual gene targets able to modulate the radioresponse, but also perhaps will enable the discovery of a novel and perhaps more efficacious class of modulators of cytotoxic therapy, miRNAs. This project will take place at Yale University, with outstanding core facilities and supporting faculty critical for guidance to obtain these goals. Course work in statistics as well as experimental design will also be pursued to give the principal investigator a solid foundation to interpret complex experimental results and design statistical analysis to bring together the extensive data generated by both the HTS as well as the miRNA analysis approaches. Over 700,000 people with cancer are treated with radiation therapy every year. A better genetic understanding of how tissues respond to radiation is critical to enable better protection of normal tissues as well as to enhance tumor cure. This work will use a novel model, Radelegans, to identify single-gene targets as well as test the potential of newly identified gene regulators (microRNAs) to accomplish these goals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08CA124484-04
Application #
7914211
Study Section
Subcommittee G - Education (NCI)
Program Officer
Myrick, Dorkina C
Project Start
2007-09-18
Project End
2012-08-31
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
4
Fiscal Year
2010
Total Cost
$138,915
Indirect Cost
Name
Yale University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Salzman, David W; Weidhaas, Joanne B (2013) SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer. Pharmacol Ther 137:55-63
Ratner, E S; Keane, F K; Lindner, R et al. (2012) A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 31:4559-66
Hollestelle, Antoinette; Pelletier, Cory; Hooning, Maartje et al. (2011) Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. Breast Cancer Res Treat 128:79-84
Paranjape, Trupti; Heneghan, Helen; Lindner, Robert et al. (2011) A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol 12:377-86
Weidhaas, Joanne B; Kirsch, David G (2011) The Holman Research Pathway in radiation oncology. Int J Radiat Oncol Biol Phys 80:321-3
Godshalk, S E; Paranjape, T; Nallur, S et al. (2011) A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma. Oncogene 30:1542-50
Pelletier, Cory; Speed, William C; Paranjape, Trupti et al. (2011) Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk. Cell Cycle 10:90-9
Chan, Elcie; Prado, Daniel Estevez; Weidhaas, Joanne Barnes (2011) Cancer microRNAs: from subtype profiling to predictors of response to therapy. Trends Mol Med 17:235-43
Chan, Elcie; Patel, Rajeshvari; Nallur, Sunitha et al. (2011) MicroRNA signatures differentiate melanoma subtypes. Cell Cycle 10:1845-52
Smits, Kim M; Paranjape, Trupti; Nallur, Sunitha et al. (2011) A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. Clin Cancer Res 17:7723-31

Showing the most recent 10 out of 19 publications